German telehealth company, Aipermon has launched a series of telemonitoring devices that will be used in a trial to explore how climate change can affect lung diseases.
The company, which is showcasing the devices at Medica in Düsseldorf this week, has partnered with medical device manufacturers Vitalograph and PARI Pharma to provide flexible modules within its traditional telemonitoring systems.
The two year trial will see the Pneumology Department at Charité, Berlin use the technology as part of a study which monitors chronic obstructive pulmonary disease and cystic fibrosis patients in terms of lung function, physical activity and their own self-assessment.
The company has integrated the Vitalograph asma-1 peak flow meter into its traditional telemetry platform.
Data from the peak flow meter, which is produced by continuously monitoring the patient, is then automatically transferred to a mobile medical assistant with special software equipment and is then made available to the medical care centre.
Aipermon technology, combined with eFlow nebulizers by PARI Pharma, will enable physicians to check whether the prescribed daily inhalation treatment for cystic fibrosis patients is implemented correctly and regularly. The device signals the date and time, duration and correct completion of each inhalation treatment.
The study, which will begin at the start of next year and will include more than 200 patients, will correlate the data collected with climate data to help scientists assess the impact on the disease by climate change and to find approaches for improving the intervention and medication